Login / Signup

An Ustilago maydis chassis for itaconic acid production without by-products.

Johanna BeckerHamed Hosseinpour TehraniMarc GauertJörg MampelLars M BlankNick Wierckx
Published in: Microbial biotechnology (2019)
Ustilago maydis is a promising yeast for the production of a range of valuable metabolites, including itaconate, malate, glycolipids and triacylglycerols. However, wild-type strains generally produce a potpourri of all of these metabolites, which hinders efficient production of single target chemicals. In this study, the diverse by-product spectrum of U. maydis was reduced through strain engineering using CRISPR/Cas9 and FLP/FRT, greatly increasing the metabolic flux into the targeted itaconate biosynthesis pathway. With this strategy, a marker-free chassis strain could be engineered, which produces itaconate from glucose with significantly enhanced titre, rate and yield. The lack of by-product formation not only benefited itaconate production, it also increases the efficiency of downstream processing improving cell handling and product purity.
Keyphrases
  • crispr cas
  • wild type
  • ms ms
  • escherichia coli
  • genome editing
  • single cell
  • type diabetes
  • cell wall
  • drug delivery
  • bone marrow
  • saccharomyces cerevisiae
  • weight loss
  • glycemic control